PUBLIC COMPANY
saveGLAXOSMITHKLINE
USupdated 15d ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of the GSK 4-component Strep A Vaccine With Aluminum Hydroxide (Alum) or AS37 in Healthy Young Adults
- phase3A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age
- phase1A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors
- phase2A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- phase3A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Healthy Japanese Adolescents Aged 11 Years to <13 Years
- phase3A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Japanese Healthy Pregnant Women
- phase3A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- phase1A Study to Investigate the Difference In Blood Levels of Camlipixant Between Different Camlipixant Formulation Prototypes
🐶 Hiring Signal
News
- FDA approves Nuvalent's cancer drug, a week after GSK closed $10.6B buyoutGSK's $10.6 billion acquisition of Nuvalent is delivering surprisingly early results. The FDA on Wednesday approved one of Nuvalent's lung cancer medicines two months earlier than projected, and th…endpoints · 23d ago
- STAT+: Pharmalittle: We’re reading about rising drug shortages, GSK coughing up a trial loss, and moreThe number of active medication shortages in the U.S. rose to 227 in the second quarter of 2026stat · 28d ago
- Beyond Boston: Unlikely cities stake biotech claimsAs Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.biopharma_dive · 1mo ago
- The hidden history of BPC-157, a favorite MAHA peptideA compound named “substance God help me” by its longtime champion could benefit from RFK Jr.'s favorable views on using peptides.stat · 2mo ago
comments(0)
5-min edit window · permanent after that